216 related articles for article (PubMed ID: 29268035)
1. Safety and efficacy of long-term treatment with teneligliptin: Interim analysis of a post-marketing surveillance of more than 10,000 Japanese patients with type 2 diabetes mellitus.
Kadowaki T; Haneda M; Ito H; Ueno M; Matsukawa M; Yamakura T; Sasaki K; Kimura M; Iijima H
Expert Opin Pharmacother; 2018 Feb; 19(2):83-91. PubMed ID: 29268035
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Safety and Efficacy of Teneligliptin in Elderly Patients with Type 2 Diabetes: Subgroup Analysis of a 3-Year Post-Marketing Surveillance in Japan.
Kadowaki T; Haneda M; Ito H; Sasaki K; Yamada Y
Adv Ther; 2020 May; 37(5):2477-2492. PubMed ID: 32323194
[TBL] [Abstract][Full Text] [Related]
3. Long-Term, Real-World Safety and Efficacy of Teneligliptin: A Post-Marketing Surveillance of More Than 10,000 Patients with Type 2 Diabetes in Japan.
Kadowaki T; Haneda M; Ito H; Sasaki K; Matsukawa M; Yamada Y
Adv Ther; 2020 Mar; 37(3):1065-1086. PubMed ID: 31873865
[TBL] [Abstract][Full Text] [Related]
4. Relationship of Eating Patterns and Metabolic Parameters, and Teneligliptin Treatment: Interim Results from Post-marketing Surveillance in Japanese Type 2 Diabetes Patients.
Kadowaki T; Haneda M; Ito H; Sasaki K; Hiraide S; Matsukawa M; Ueno M
Adv Ther; 2018 Jun; 35(6):817-831. PubMed ID: 29777520
[TBL] [Abstract][Full Text] [Related]
5. Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan.
Kadowaki T; Inagaki N; Watada H; Sasaki K; Mori-Anai K; Iwasaki T; Teranishi T
Adv Ther; 2022 Apr; 39(4):1642-1658. PubMed ID: 35138572
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.
Kadowaki T; Kondo K
Diabetes Obes Metab; 2014 May; 16(5):418-25. PubMed ID: 24205974
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes.
Kadowaki T; Inagaki N; Kondo K; Nishimura K; Kaneko G; Maruyama N; Nakanishi N; Watanabe Y; Gouda M; Iijima H
Diabetes Obes Metab; 2018 Jan; 20(1):77-84. PubMed ID: 28608617
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of teneligliptin in Japanese patients with type 2 diabetes mellitus: a pooled analysis of two Phase III clinical studies.
Kadowaki T; Marubayashi F; Yokota S; Katoh M; Iijima H
Expert Opin Pharmacother; 2015 May; 16(7):971-81. PubMed ID: 25861982
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of teneligliptin add-on to insulin monotherapy in Japanese patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled trial with an open-label period.
Kadowaki T; Kondo K; Sasaki N; Miyayama K; Yokota S; Terata R; Gouda M
Expert Opin Pharmacother; 2017 Sep; 18(13):1291-1300. PubMed ID: 28741385
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of canagliflozin in elderly patients with type 2 diabetes mellitus: a 1-year post-marketing surveillance in Japan.
Goda M; Yamakura T; Sasaki K; Tajima T; Ueno M
Curr Med Res Opin; 2018 Feb; 34(2):319-327. PubMed ID: 29025285
[TBL] [Abstract][Full Text] [Related]
11. Real-World Safety and Effectiveness of Canagliflozin Treatment for Type 2 Diabetes Mellitus in Japan: SAPPHIRE, a Long-Term, Large-Scale Post-Marketing Surveillance.
Inagaki N; Nangaku M; Sakata Y; Sasaki K; Mori-Anai K; Iwasaki T; Hamada K
Adv Ther; 2022 Jan; 39(1):674-691. PubMed ID: 34853985
[TBL] [Abstract][Full Text] [Related]
12. The Durable Safety and Effectiveness of Lixisenatide in Japanese People with Type 2 Diabetes: The Post-Marketing Surveillance PRANDIAL Study.
Terauchi Y; Usami M; Inoue T
Adv Ther; 2022 Jun; 39(6):2873-2888. PubMed ID: 35449321
[TBL] [Abstract][Full Text] [Related]
13. Safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): Interim results of a post-marketing surveillance study.
Terauchi Y; Yokote K; Nakamura I; Sugamori H
Expert Opin Pharmacother; 2016; 17(4):463-71. PubMed ID: 26800061
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus.
Kadowaki T; Kondo K
Diabetes Obes Metab; 2013 Sep; 15(9):810-8. PubMed ID: 23464664
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes.
Otsuki H; Kosaka T; Nakamura K; Shimomura F; Kuwahara Y; Tsukamoto T
Int Urol Nephrol; 2014 Feb; 46(2):427-32. PubMed ID: 24014134
[TBL] [Abstract][Full Text] [Related]
16. Safety and effectiveness of ipragliflozin in elderly versus non-elderly Japanese type 2 diabetes mellitus patients: 12 month interim results of the STELLA-LONG TERM study.
Maegawa H; Tobe K; Nakamura I; Uno S
Curr Med Res Opin; 2019 Nov; 35(11):1901-1910. PubMed ID: 31347926
[No Abstract] [Full Text] [Related]
17. Long-Term Safety and Efficacy of Sitagliptin for Type 2 Diabetes Mellitus in Japan: Results of a Multicentre, Open-Label, Observational Post-Marketing Surveillance Study.
Yoshikawa K; Tsuchiya A; Kido T; Ota T; Ikeda K; Iwakura M; Maeda Y; Maekawa S
Adv Ther; 2020 May; 37(5):2442-2459. PubMed ID: 32306246
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, placebo-controlled, parallel-group comparative study.
Kadowaki T; Inagaki N; Kondo K; Nishimura K; Kaneko G; Maruyama N; Nakanishi N; Gouda M; Iijima H; Watanabe Y
Diabetes Obes Metab; 2018 Feb; 20(2):453-457. PubMed ID: 28786530
[TBL] [Abstract][Full Text] [Related]
19. Real-World Evidence for Long-Term Safety and Effectiveness of Ipragliflozin in Japanese Patients with Type 2 Diabetes Mellitus: final Results of a 3-Year Post-Marketing Surveillance Study (STELLA-LONG TERM).
Nakamura I; Maegawa H; Tobe K; Uno S
Expert Opin Pharmacother; 2021 Feb; 22(3):373-387. PubMed ID: 33012212
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of ipragliflozin in elderly versus non-elderly Japanese patients with type 2 diabetes mellitus: a subgroup analysis of the STELLA-LONG TERM study.
Maegawa H; Tobe K; Tabuchi H; Nakamura I; Uno S
Expert Opin Pharmacother; 2018 Mar; 19(4):327-336. PubMed ID: 29388470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
